Quantbot Technologies LP Cel Sci Corp Transaction History

Quantbot Technologies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$2.17 - $3.13 $2,558 - $3,690	-1,179 Reduced 51.33%	1,118 $2,000
Q4 2022 Feb 13, 2023	SELL	$1.99 - $3.52 $1,393 - $2,464	-700 Reduced 23.36%	2,297 $5,000
Q3 2022 Nov 07, 2022	BUY	$3.09 - $5.23 $6,788 - $11,490	2,197 Added 274.63%	2,997 $9,000
Q2 2022 Aug 09, 2022	BUY	$2.58 - $4.99 $2,064 - $3,992	800 New	800 $3,000
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $81,857 - $160,383	-20,829 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$7.1 - $12.82 $109,240 - $197,248	15,386 Added 282.67%	20,829 $147,000
Q3 2021 Nov 09, 2021	BUY	$7.64 - $12.49 $19,428 - $31,762	2,543 Added 87.69%	5,443 $59,000
Q2 2021 Aug 12, 2021	BUY	$8.68 - $27.49 $25,172 - $79,721	2,900 New	2,900 $25,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.